{"schema_version":"secwatch.filing_event.v1","accession":"0000950103-21-015724","form_type":"8-K","ticker":"PGEN","cik":"0001356090","company_name":"PRECIGEN, INC.","filed_at":"2021-10-12T23:59:59+00:00","discovered_at":"2026-05-14T18:04:12.230111+00:00","generated_at":"2026-06-28T21:21:33.485893+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Precigen appoints Harry Thomasian Jr. as CFO effective Oct 18, 2021","bullets":["Harry Thomasian Jr., 59, appointed CFO, effective October 18, 2021; succeeds interim CFO James V. Lambert.","Thomasian previously a partner at EY for 19 years, life sciences and capital markets experience.","Compensation: base salary $440,000.16, target annual bonus 40% of base, stock options for 180,000 shares vesting over 4 years.","Appointment fills CFO role vacant since Rick Sterling resigned April 2021; search completed."],"urls":{"canonical":"https://secwatch.observer/filing/0000950103-21-015724","json":"https://secwatch.observer/filing/0000950103-21-015724.json","markdown":"https://secwatch.observer/filing/0000950103-21-015724.md","text":"https://secwatch.observer/filing/0000950103-21-015724.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1356090/000095010321015724/0000950103-21-015724-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1356090/000095010321015724/dp159662_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T21:21:33.485893+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"15b82ced62","claim":"James V. Lambert changed role as Interim Principal Accounting Officer at PRECIGEN, INC..","evidence_excerpt":"James V. Lambert, who has served as interim principal accounting officer of the Company since Mr. Osborne's resignation, will step down from that position effective upon Mr. Thomasian's start date, and will continue to serve as Executive Director, Finance for PGEN Therapeutics, Inc., a wholly owned subsidiary of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1356090/000095010321015724/0000950103-21-015724-index.htm","confidence":0.9,"family_label":"Executive change","details":[{"label":"Action","value":"stepped down"},{"label":"Role","value":"Interim Principal Accounting Officer"}],"fact_type":"executive_change"},{"claim_id":"c868b25f64","claim":"Harry Thomasian Jr. was appointed as Chief Financial Officer at PRECIGEN, INC..","evidence_excerpt":"On October 12, 2021, Precigen, Inc. (the “Company”), announced that Harry Thomasian Jr., age 59, was appointed Chief Financial Officer of the Company, effective October 18, 2021.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1356090/000095010321015724/0000950103-21-015724-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}